You are here

Keytruda

Catching up with Roche, Merck racks up positive data in frontline triple negative breast cancer

Catching up with Roche, Merck racks up positive data in frontline triple negative breast cancer

Endpoints

triple negative breast cancer

clinical trials

Flag link:

BeiGene’s Tislelizumab Could Challenge Merck’s Keytruda in the Checkpoint Inhibitor Market

BeiGene’s Tislelizumab Could Challenge Merck’s Keytruda in the Checkpoint Inhibitor Market

BioSpace

non-small cell lung cancer

Flag link:

Merck's Blockbuster Drug Wins Key New FDA Approval

Merck's Blockbuster Drug Wins Key New FDA Approval

Motley Fool

Flag link:

US cancer death rate drops by sharpest rate on record

US cancer death rate drops by sharpest rate on record

BioPharma Dive

Bristol-Myers Squibb

Flag link:

Merck’s Keytruda Shows Mixed Results in Lung Cancer Study

Merck’s Keytruda Shows Mixed Results in Lung Cancer Study

BioSpace

small cell lung cancer

Flag link:

Merck’s Keytruda nabs FDA panel's favor to line up for new bladder cancer OK

Merck’s Keytruda nabs FDA panel's favor to line up for new bladder cancer OK

Fierce Pharma

Flag link:

Merck Isn't Too Reliant on Keytruda Yet, and That's Good News for Investors

Merck Isn't Too Reliant on Keytruda Yet, and That's Good News for Investors

Motley Fool

Flag link:

Merck's Keytruda is bound for new bladder cancer territory. But can it hold up against gene therapy?

Merck's Keytruda is bound for new bladder cancer territory. But can it hold up against gene therapy?

Fierce Pharma

nadofaragene firadenovec

Flag link:

Merck’s Keytruda gets FDA priority review for high-risk NMIBC

Merck’s Keytruda gets FDA priority review for high-risk NMIBC

Pharmaceutical Business Review

priority review

Flag link:

Merck's Keytruda lung cancer sales may face new pressure, but investors shouldn't sweat it: analyst

Merck's Keytruda lung cancer sales may face new pressure, but investors shouldn't sweat it: analyst

Fierce Pharma

non-small cell lung cancer

Flag link:

Regeneron defends bid to challenge Merck in lung cancer

Regeneron defends bid to challenge Merck in lung cancer

Biopharma Dive

immuno-oncology

Flag link:

Should Merck Investors Worry About Bristol Myers' Lung Cancer Drug Results?

Should Merck Investors Worry About Bristol Myers' Lung Cancer Drug Results?

Motley Fool

Bristol-Myers Squibb

Flag link:

Bristol-Myers warns I-O blockbuster Opdivo will be 'under pressure' in 2020

Bristol-Myers warns I-O blockbuster Opdivo will be 'under pressure' in 2020

Fierce Pharma

Bristol-Myers Squibb

Flag link:

Merck CFO: we’re not only about Keytruda

Merck CFO: we’re not only about Keytruda

PM Live

Flag link:

Merck beats estimates as Keytruda sales top $3 billion for first time

Merck beats estimates as Keytruda sales top $3 billion for first time

Yahoo/Reuters

Flag link:

Merck, BMS, AbbVie blockbusters will rule pharma sales in 2025: report

Merck, BMS, AbbVie blockbusters will rule pharma sales in 2025: report

Fierce Pharma

Bristol-Myers Squibb

Flag link:

Merck’s KEYTRUDA approved as monotherapy in China for first-line treatment of certain patients with advanced NSCLC

Merck’s KEYTRUDA approved as monotherapy in China for first-line treatment of certain patients with advanced NSCLC

Pharmaceutical Business Review

non-small cell lung cancer

Flag link:

ESMO: Merck, Eisai detail Keytruda-Lenvima combo results after triple endometrial cancer OK

ESMO: Merck, Eisai detail Keytruda-Lenvima combo results after triple endometrial cancer OK

Fierce Pharma

endometrial cancer

Flag link:

Merck, Pfizer execs explain how they tap sites for cancer trials

Merck, Pfizer execs explain how they tap sites for cancer trials

Biopharma Dive

clinical trials

immuno-oncology

Flag link:

Biotechs Fly Sideways In Quiet Week — 5 News Items You May Have Missed

Biotechs Fly Sideways In Quiet Week — 5 News Items You May Have Missed

Investors Business Daily

Wave Life Sciences

Jazz Pharmaceuticals

Flag link:

Pages